AOD-9604

Overview

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. It stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full HGH.

Mechanism of Action

AOD-9604 mimics the lipolytic action of natural growth hormone by interacting with the beta-3 adrenergic receptor pathway in adipose tissue. It stimulates the breakdown of stored triglycerides and inhibits the formation of new fat cells without binding to the GH receptor or affecting IGF-1 levels.

Research Summary

Phase 2 clinical trials showed modest weight loss in obese subjects over 12 weeks. Preclinical studies demonstrate significant fat reduction without affecting lean mass or glucose homeostasis. It has FDA GRAS (Generally Recognized As Safe) status for food use.

Dosing Information

Reported Side Effects

• Injection site redness
• Headache
• Mild nausea
• Chest tightness (rare)

Research References

• A double-blind, placebo-controlled study of the effects of hGH fragment 176-191 on body composition in obese subjects (2001)
• AOD9604: a novel approach to the treatment of obesity (2004)
• Metabolic effects of a synthetic lipolytic domain (AOD9604) of human growth hormone (1999)